Supernus Pharm (NASDAQ: SUPN) reported Q2 EPS of ($5.17), $4.71 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $750 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Supernus Pharm (SUPN) click here.

Earnings